Pharmacological inhibition (García-Rivas Gde et al., 2006; Xie et al., 2018) or genetic ablation (Kwong et al., 2015; Luongo et al., 2015) of MCU, as well as conditional NCLX overexpression (Luongo et al., 2017) has been shown to protect against ischemia-induced myocyte injury, the development Ca2+-dependent arrhythmia and the progression of HF. This evidence concerns the gene SLC8B1 and hydrops fetalis.